Form 4 CHIMERIX INC For: May 04 Filed by: MARIO ERNEST
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Chimerix (CMRX) Tops Q1 EPS by 9c; Interim Topline Advise Data Provided, AdV Level Reduction Noted
May 9, 2016 7:33 AM EDTChimerix (NASDAQ: CMRX) reported Q1 EPS of ($0.57), $0.09 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $2.79 million.
Today, Chimerix provided topline results from an interim analysis of week 24 data from AdVise which shows a strong antiviral effect which was correlated with overall survival. The company is working closely with medical advisors to plan a prospective, comparative trial in patients with serious adenovirus (AdV) infection.
In August 2015, the Company completed enrollment of the AdVise trial of brincidofovir (BCV) as a... More
